Fujirebio developing companion diagnostic for Morphotek's farletuzumab

The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide rights to develop and commercialize the CA125 II assay as a companion diagnostic to identify ovarian cancer patients who may best respond to Morphotek's farletuzumab, a humanized IgG1 antibody targeting the folate receptor 1 (FOLR1; FR-alpha). The candidate has been evaluated in combination with carboplatin plus taxane to treat relapsed, platinum-sensitive ovarian cancer in a Phase III trial...